Method of treating amyotrophic lateral sclerosis
AssigneeWoolsey Pharmaceuticals, Inc.
InventorsThomas MACALLISTER, Sven JACOBSON
Life of this patent
Estimating the term…
Abstract
The present invention relates to the treatment of a sporadic ALS patient with oral fausdil at a dose of 180-240 mg/day. This results in an anticipated 25-50% reduction in the average decline over at least three months as measured using the revised ALS Functional Rating Scale.
Claims20
A method of treating a patient with possible, probable laboratory-supported, probable, or definite sporadic amyotrophic lateral sclerosis (ALS), as defined by El Escorial Revised ALS diagnostic criteria, comprising orally administering a therapeutically effective amount of fasudil or M3, wherein the therapeutically effective dose of fasudil hydrochloride is 90 mg/day or higher.
A method of treating a patient with possible, probable laboratory-supported, probable, or definite sporadic amyotrophic lateral sclerosis (ALS), as defined by El Escorial Revised ALS diagnostic criteria, comprising orally administering a therapeutically effective amount of fasudil or M3, wherein the therapeutically effective amount is sufficient to result in a reduction in neurofilament light chain.
Dependencies are inferred from the claim text.